Dogecoin Cash, Inc.

Dogecoin Cash, Inc., through its subsidiaries, provides telemedicine online referral services for customers desiring medical marijuana cards in the United States. The company offers PrestoDoctor, an online telemedicine platform, which provides access to physicians for getting a medical marijuana recommendation using video conferencing technology. It also develops Lozenges for relief; Recover, a deep penetrating healing balm used to relieve pain for sore muscles, joints, arthritic, and back pain; Trauma Cream, a cream for blended infusion of cannabinoids and THC, as well as intends to offer hi branded men's and women's fashion from suppliers through its www.cbds.com website. In addition, the company holds intellectual property license for manufacture of medical marijuana edibles. It serves cannabidiol and cannabis industries. The company was formerly known as Cannabis Sativa, Inc. and changed its name to Dogecoin Cash, Inc. in November 2024. Dogecoin Cash, Inc. is based in Mesquite, Nevada.

Dogecoin Cash, Inc. trades as DOGP on OTC. The company is classified in Healthcare / Medical - Healthcare Information Services and reports in USD.

The current profile places the business in Medical - Healthcare Information Services. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Dogecoin Cash, Inc. can be compared against peers such as CompuMed, Inc., Cann Group Limited, HealthLynked Corp., IR-Med Inc., Lifeline Biotechnologies, Inc., Revive Therapeutics Ltd..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $2.20M, beta of 2.50, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

DOGP currently shows total debt of N/A and beta of 2.50. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.dogecoincashinc.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.